Cite Score:
0.25
ELSEVIER SCOPUS

Assessment of the Relationship between Galectin-3 and Ejection Fraction and Functional Capacity in the Patients with Compensated Systolic Heart Failure

AUTHORS

Roya Atabakhshian 1 , Faranak Kazerouni 1 , * , Fariba Raygan 2 , Hushang Amirrasouli 1 , Ali Rahimipour 1 , Nezhat Shakeri 3

AUTHORS INFORMATION

1 Department of Laboratory Medicine, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2 Heart Department, Shahid Beheshti Hospital, Shahid Beheshti University of Medical Sciences, Kashan, Iran

3 Department of Biostatistics, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

How to Cite: Atabakhshian R , Kazerouni F, Raygan F , Amirrasouli H , Rahimipour A , et al. Assessment of the Relationship between Galectin-3 and Ejection Fraction and Functional Capacity in the Patients with Compensated Systolic Heart Failure, Int Cardio Res J. 2017 ; 8(4):e11675.

ARTICLE INFORMATION

International Cardiovascular Research Journal: 8 (4); e11675
Published Online: December 01, 2014
Article Type: Research Article
Received: April 19, 2017
Accepted: May 14, 2014

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background: Galectin-3 is a soluble ß-galactoside–binding lectin released by activated cardiac macrophages. Galectin-3 has been proposed for diagnosis and prognosis of HF patients.

Objectives: The present study aimed to investigate the relationship between galectin-3 as a biomarker and ejection fraction and functional capacity in the patients with compensated systolic heart failure.

Patients and Methods: In this study, serum levels of Galectin-3 were measured in 76 patients with compensated heart failure with New York Heart Association class I–IV and left ventricular ejection fraction < 45%. Galectin-3 was measured by an ELISA kit. Besides, echocardiography was used to evaluate left ventricular ejection fraction. Additionally, functional capacity was determined based on the patients’ ability to perform a set of activities. After all, the data were analyzed used t-test, Kruskal-Wallis, one–way ANOVA, and chi-square test. P < 0.05 was considered as statistically significant.

Results: The patients’ age ranged from 45 to 75 years, with the mean age of 63.85 ± 9 years. In addition 57.9% of the patients were male. The results revealed no significant correlation between Galectin-3 and age, body mass index, and estimated glomerular filtration rate. Also, no significant correlation was observed between Galectin-3 levels and left ventricular ejection fraction (P = 0.166) and functional capacity (P = 0.420). Yet, a significant difference was found between males and females regarding the mean of Galectin-3 (P = 0.039).

Conclusions:: The study results suggested that Galectin-3 could not be used as a marker of disease progression in the patients under treatment, which could probably be the result of medication use in these patients.

Keywords

Galectin-3,Heart Failure,Functional Capacity

© 0, Shiraz University of Medical Sciences.

Fulltext

The full text is available in PDF.

References

  • 1. The references are available in PDF.
  • COMMENTS

    LEAVE A COMMENT HERE: